Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$114.48 USD
-1.69 (-1.45%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $114.50 +0.02 (0.02%) 6:16 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$114.48 USD
-1.69 (-1.45%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $114.50 +0.02 (0.02%) 6:16 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Zimmer Biomet (ZBH) Down 2.9% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Zimmer Biomet (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zimmer Biomet New System Gets FDA Nod, to Boost Spine Wing
by Zacks Equity Research
Zimmer Biomet (ZBH) receives FDA's approval for the new system, which is likely to augment the company's lumbar spacers portfolio.
Generac, Maximus, Norbord, Boeing and Zimmer Biomet as Zacks Bull and Bear of the Day
by Zacks Equity Research
Generac, Maximus, Norbord, Boeing and Zimmer Biomet as Zacks Bull and Bear of the Day
3 Stocks Back In Play After U.S.-China Trade War Stalls
by Taye Baldinazzo
On Sunday, the U.S. and China put trade tensions aside in hopes of reaching a stable and broad trade agreement. With previously at-risk stocks beginning to rise, there seems to be room for profit in these formerly questionable markets. Read on for three stocks that investors should reconsider as the trade war is put on hold.
Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, Margins Drop
by Zacks Equity Research
Zimmer Biomet (ZBH) issues full-year 2018 sales and earnings guidance in Q1.
Zimmer Biomet (ZBH) Beats on Q1 Earnings & Revenue Estimates
by Zacks Equity Research
Zimmer Biomet (ZBH) rides on strength in Knee, Hip and S.E.T. segments in Q1.
Can S.E.T. Aid Zimmer (ZBH) Q1 Earnings Despite Supply Woes?
by Zacks Equity Research
Several FDA clearances within S.E.T since last November raise hope for Zimmer Biomet (ZBH) in Q1.
Supply Delay Hits Zimmer Biomet, Operational Plan Buoys Hope
by Zacks Equity Research
Zimmer Biomet's (ZBH) dull Knee sales continue to bother due to slower pace of supply recovery and sales recapture of certain key brands.
Trade War Fears Grip MedTech: 3 Stocks on the Line of Fire
by Urmimala Biswas
Chances of a retaliation from China leads to widespread losses in the medical device sector.
New Strong Sell Stocks for February 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Zimmer Biomet (ZBH) Q4 Earnings Meet, Sales Miss Estimates
by Zacks Equity Research
Zimmer Biomet (ZBH) rides high on all segments.
Will S.E.T. Arm Drive Zimmer Biomet's (ZBH) Q4 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) poised to gain on strength in S.E.T as well as Spine & CMF segments in Q4.
Zimmer Biomet Strong on Positive Data From PROGRESS II Study
by Zacks Equity Research
Zimmer Biomet (ZBH) consistently endeavors to improve its knee business.
Zimmer Biomet (ZBH) Surges: Stock Moves 6.1% Higher
by Zacks Equity Research
Zimmer Biomet (ZBH) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.
New Strong Sell Stocks for December 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Zimmer Biomet Hurt by Supply Delay, Knee Challenges Remain
by Zacks Equity Research
Zimmer Biomet (ZBH) struggles with supply delay problem related to some of its products, causing inability to win back lost customers and gain new ones.
New Strong Sell Stocks for November 20th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Zimmer Biomet (ZBH) Misses Q3 Earnings, Meets Sales Estimate
by Zacks Equity Research
Zimmer Biomet (ZBH) posts in line revenues on the back of soft Knees and Hips segments in Q3.
5 Earnings All-Stars to Start the Week
by Tracey Ryniec
With over 1,000 companies reporting, these are some of the best earnings charts to start the week.
Will S.E.T. Arm Drive Zimmer Biomet's (ZBH) Q3 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) poised to gain on strength in S.E.T as well as Spine & CMF segments in Q3.
Is Zimmer Biomet (ZBH) a Great Stock for Value Investors?
by Zacks Equity Research
Is Zimmer Biomet (ZBH) a great pick from the value investor's perspective right now? Read on to know more.
Zimmer Biomet (ZBH) Launches Persona Partial Knee System
by Zacks Equity Research
Zimmer Biomet (ZBH) is constantly trying to turn its Knees business around. Keeping in line with the efforts, the company has launched Persona Partial Knee System.
New Strong Sell Stocks for September 6th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Zimmer (ZBH) Plagued by Various Internal and External Issues
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to suffer a bad patch, entangled with issues including its decade-old CEO's recent exit post a dull earnings season due to poor knee business.
New Strong Sell Stocks for August 14th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: